Product
Resiniferatoxin
Aliases
RTX
4 clinical trials
10 indications
Indication
PainIndication
IntractableIndication
CancerIndication
OsteoarthritisIndication
KneeIndication
Osteoarthritis, KneeIndication
Chronic Knee PainIndication
Morton's NeuromaIndication
Intractable PainIndication
Palliative CareClinical trial
A Multicenter, Phase 2 Study to Assess the Safety and Efficacy of Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced CancerStatus: , Estimated PCD: 2027-06-01
Clinical trial
A Phase 2, Randomized, Active and Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee OsteoarthritisStatus: Active (not recruiting), Estimated PCD: 2023-09-01
Clinical trial
Phase I Open Label Clinical Trial Using Resiniferatoxin, A Non-Opioid Medication, For the Management of Refractory Morton's Neuroma PainStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
An Open-Label, Phase 1b Safety and Efficacy Trial of Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone PainStatus: Not yet recruiting, Estimated PCD: 2026-12-01